Is Buying THROMBOGENICS NV ORDINARY SHARES BELGIU (OTCMKTS:TBGNF), Having Lower Short Interest a Winning Strategy?

July 13, 2018 - By Mary Markley

ThromboGenics NV (OTCMKTS:TBGNF) Logo

The stock of THROMBOGENICS NV ORDINARY SHARES BELGIU (OTCMKTS:TBGNF) registered a decrease of 1.18% in short interest. TBGNF’s total short interest was 58,600 shares in July as published by FINRA. Its down 1.18% from 59,300 shares, reported previously. With 100 shares average volume, it will take short sellers 586 days to cover their TBGNF’s short positions. The short interest to THROMBOGENICS NV ORDINARY SHARES BELGIU’s float is 0.19%.

It closed at $9.075 lastly. It is down 0.00% since July 13, 2017 and is . It has underperformed by 12.57% the S&P500.

ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The company has market cap of $355.15 million. The company's lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has a 11.89 P/E ratio. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.